GlycoMimetics, Inc. (GLYC) Q4 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and thank you for joining the GlycoMimetics Q4 and full year 2023 earnings call. At this time, all participants are on a listen-only mode. Following management's remarks, we will hold a question and answer session. At that time, lines will be open for you. I would like to turn the call over to Christian Deneen Long, Company Counsel at GlycoMimetics. Please go ahead. Good morning. Today we will review our business updates and financial results for the quarter and year ended December 31, 2023. The press release we issued this morning is available on the company's website at glycomimetics.com. This call is being recorded, and a dial-in phone replay will be available for 24 hours after the close of the call. The webcast replay will also be available for 30 days in the Investors section of the company's website. On the call today from Glycomimetics are Harut Samarjan, Chief Executive Officer, Brian Hahn, Chief Financial Officer, Dr. Edwin Rock, Chief Medical Officer, and Bruce Johnson, Chief Commercial Officer. Today's call will include forward-looking statements based on our current expectations. Forward-looking statements may include, but are not limited to, statements about the company's product candidates, Yupra-Lessolan and GMI 1687, the progress and timing of clinical trials being conducted by us or our collaborators, including our expectations regarding data readout from those trials, planned or potential regulatory agency interactions or submissions, development plans and activities, pre-launch preparations, and the company's cash position and runway. Such statements represent management's judgment and intention as of today and involve assumptions, risks, and uncertainties. Glycomimedex undertakes no obligation to update or revise any forward-looking ...